Health
Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF – TCTMD
Prospective studies are needed and mechanisms unclear, but the findings raise hopes for off-target benefits, says J. Emanuel Finet.
Compared with valsartan alone, the angiotensin receptor-neprilysin inhibitor (ARNI) / (Entresto; Novartis) reduces triglycerides among patients with heart failure and preserved ejection fraction (HFpEF), according to results from a PARAGON-HF subanalysis. The effect was particularly marked in patients with higher triglycerides at baseline.
Our research adds to the growing literature of the favorable metabolic effects of sacubitril/valsartan, Senthil Selvaraj, MD (Hospital of the University of Pennsylvania,…
-
Noosa News16 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News21 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up
-
Noosa News14 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News23 hours agoDifficult to diagnose and potentially deadly — this lesser-known disease is becoming more common